Annovis Announces Launch of Proposed Public Offering

Annovis intends to direct offering proceeds toward buntanetap clinical studies in Alzheimer’s and Parkinson’s diseases.

Rhea-AI Summary

Annovis Bio (NYSE: ANVS) announced a proposed underwritten public offering of common stock or pre-funded warrants, together with accompanying warrants.

The securities will be issued separately but can only be purchased together. All securities will be offered by Annovis, with Canaccord Genuity acting as sole bookrunner. Annovis intends to use net proceeds to continue clinical development of buntanetap in Alzheimer’s and Parkinson’s disease studies, as well as for working capital and general corporate purposes. The offering remains subject to market and other conditions; its completion, timing, size and terms are not assured.

1 point · 0 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate point. Forward-looking: it has not happened yet and may not happen.Proposed offering would raise funding for continued buntanetap clinical development in Alzheimer’s and Parkinson’s disease studies.

Negative

• Moderate point. Forward-looking: it has not happened yet and may not happen.Proposed common stock or pre-funded warrants, plus accompanying warrants would dilute holders through share issuance or exercise.
• Minor pointOffering remains subject to market and other conditions, with completion and timing uncertain.

News Explained

If completed, the proposed offering could reduce existing holders’ ownership percentages: Annovis would issue common shares or pre-funded warrants alongside warrants exercisable for shares, but this release states no quantities with which to assess the possible dilution.

Argus 15 min delay 33 alerts

-24.05% vs previous close $0.9190 last price 2.0x rel. volume Open Argus

Details

Market move: ANVS -24.05% vs previous close. proposed public offering

-17.6% Trough in 3 min

$0.85 – $1.25 Day Range

$39.22M Mkt Cap at Last Price

On Nov 4, the day this news came out, the latest delayed price for ANVS is 24.05% below the previous close. Argus tracked a trough of -17.6% from its starting point during tracking. Our momentum scanner has recorded 33 alerts for this stock so far that day. The latest delayed price is $0.92. Relative volume is above average at 2.0x what this stock usually trades by this time of day.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Terms

underwritten public offering, pre-funded warrants, shelf registration statement, form s-3, +1 more

5 terms

underwritten public offering financial

"announced a proposed underwritten public offering"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

pre-funded warrants financial

"pre-funded warrants to purchase shares of its common stock"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

shelf registration statement regulatory

"pursuant to an effective shelf registration statement on Form S-3"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"an effective shelf registration statement on Form S-3"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

prospectus supplement regulatory

"A preliminary prospectus supplement and accompanying prospectus"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced a proposed underwritten public offering in which it intends to offer and sell (i) shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, and (ii) accompanying warrants to purchase shares of common stock. The shares of common stock (or pre-funded warrants in lieu thereof) and the accompanying warrants will be issued separately but can only be purchased together in the proposed offering. All of the securities in the proposed offering will be offered by Annovis. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Canaccord Genuity is acting as the sole bookrunner in the offering.

Annovis intends to use the net proceeds from the offering for the continued clinical development of its lead compound buntanetap in clinical studies for Alzheimer’s disease (AD) and Parkinson’s disease (PD), and for working capital and general corporate purposes.

The securities described above are being offered by Annovis pursuant to an effective shelf registration statement on Form S-3, as amended (No. 333-276814), initially filed with the Securities and Exchange Commission (SEC) on February 1, 2024 and declared effective by the SEC on February 12, 2024. A preliminary prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC. When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained from: Canaccord Genuity LLC, Attention: Syndication Department, One Post Office Square, 30th Floor, Boston, Massachusetts 02109, or by email at prospectus@cgf.com. Electronic copies of the preliminary prospectus supplement and accompanying prospectus will also be available on the SEC’s website at http://www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or other jurisdiction.

About Annovis

Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The Company’s lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

Forward-Looking Statements

This press release contains forward-looking statements under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the consummation of the offering, the satisfaction of closing conditions and the intended use of proceeds from the offering. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.

Contact Information:

Annovis Bio, Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com

Investor Contact:

Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What securities is Annovis Bio proposing to sell in its public offering?

Annovis proposes to sell common stock or pre-funded warrants, together with accompanying warrants to purchase common stock. The securities will be issued separately but can only be purchased together. All securities in the proposed offering will be offered by Annovis.

How does Annovis Bio plan to use the public offering proceeds?

Annovis intends to use the net proceeds for continued clinical development of buntanetap in Alzheimer’s and Parkinson’s disease studies, and for working capital and general corporate purposes.